Background-Antiarrhythmic drugs (AADs) are used to reduce the frequency, severity, and duration of atrial fibrillation (AF) events, which should reduce hospitalizations; however, little is known about the associations between different AADs and hospitalization-particularly among younger AF patients without structural heart disease. Methods and Results-Using MarketScan® claims data, we identified AF patients without coronary artery disease or heart failure who received their first AAD prescription (amiodarone, sotalol, dronedarone, or Class Ic) within 14 days post-first AF encounter. The primary outcome was time from first AAD prescription to AF hospitalization, and secondary outcomes included time to cardiovascular and all-cause hospitalizations. We used inverse probability-weighted estimators to adjust for differences in treatment allocation in the Cox proportional hazards model for each outcome. Among 8562 AF patients with a median age of 56 years (interquartile range 49, 61), risk of AF hospitalization was greater with dronedarone than Class Ic (hazard ratio [HR] 1.59; 95% confidence interval 1.13-2.24), amiodarone (HR 2.63; 1.77-3.89), and sotalol (HR 1.72; 1.17-2.54), but lower with amiodarone versus Class Ic (HR 0.68; 0.57-0.80) and sotalol (HR 0.63; 0.53-0.75). Risk of cardiovascular hospitalization was lower with amiodarone than Class Ic (HR 0.80; 0.70-0.92), but not non-AF cardiovascular hospitalization (HR 1.26; 1.01-1.57). There was no difference in all-cause hospitalization between amiodarone, Class Ic, and sotalol. Conclusions-Differences in hospitalization rates were found between AADs in younger AF patients without structural heart disease. Amiodarone had the lowest risk of AF hospitalization and dronedarone had the greatest risk. Additional research is needed to better understand associations between AADs and hospitalization risk. (Circ Cardiovasc Qual Outcomes. 2015;8:292-300.
T he symptoms and risks associated with atrial fibrillation (AF) and the available treatments for AF vary widely among patients; therefore, treatment options range from simple symptom management to more complex invasive medical procedures. [1] [2] [3] [4] One or more hospitalizations may be required for treatment of AF or management of AF-related adverse events or treatments. [5] [6] [7] [8] Several studies have shown a greater risk of hospitalization in patients with AF versus those without, and there has been an increase in hospitalization rates among AF patients over the past several decades. [6] [7] [8] Most of these studies have primarily included older AF patients with comorbidities like cardiovascular disease. Regardless of the reason, hospitalizations are often a burden to the patient and the healthcare system. Furthermore, cardiovascular hospitalizations for AF patients have been shown to be associated with a significantly greater risk of mortality. 5, 9 The use of antiarrhythmic drugs (AADs) is one approach to AF management and, in select populations, the use of some AADs have been associated with a reduced risk of AF and cardiovascular hospitalizations compared with placebo or a rate control strategy. [9] [10] [11] [12] [13] Nevertheless, little is known about hospitalization rates among AF patients with AADs in clinical practice, particularly among younger patients without concomitant heart disease. The purpose of our study was to compare hospitalization rates after the initiation of different AADs in clinical practice among AF patients <65 years of age who did not have coronary artery disease (CAD) or heart failure.
Methods
Data from the Thomas Reuters MarketScan® Commercial Claims and Encounters Database were used to identify a study cohort of AF patients without CAD or heart failure who were started on an AAD.
The MarketScan database used in this study included individual-level inpatient, outpatient, and prescription claims data from United States (US) employers who provide health plans for their employees and employees' spouses and dependents. Medicare claims data were not included, and all patients in the study cohort were <65 years of age. This data source has been used primarily for healthcare utilization and outcomes studies in a variety of diseases, including AF. [14] [15] [16] [17] [18] The database includes medical and surgical claims for inpatient and outpatient services, inpatient admission data, inpatient/outpatient facility data, outpatient prescription medication claims, and beneficiary enrollment data. Beneficiaries include active employees, early retirees, Consolidated Omnibus Budget Reconciliation Act continuation coverage recipients, and their dependents insured by employer-sponsored plans. The types of plans include Basic/Major Medical, Comprehensive, Exclusive Provider Organizations, Health Maintenance Organizations, Point of Service, Consumer-Driven Health Plans, and High Deductible Health Plans. Approximately 100 payers, including commercial insurance companies, Blue Cross Blue Shield plans, and third party administrators contribute data to the database. Each beneficiary has a unique enrollee identification code that is created based on the data contributor, encrypted employee identifier, relationship of enrollee to the contract holder, sex of enrollee, and enrollee data of birth. The specific methodology for deriving an enrollee identification may vary between data contributors based on the number of these factors that are provided. For our study, only data provided at the person-level were used. Reasonableness checks on the data are conducted, which assess the relationship between ≥2 fields to ensure they are reasonable against norms, such as checking diagnosis against age and diagnosis against sex. Validity checks are done on selected fields, such as zip codes, diagnosis codes, procedure codes, and so on to compare recorded values to lists of all possible valid values. Improper coding is communicated to the carrier in an attempt to improve future reporting. The claims lag period varies among the data contributors and the type of data. For this study, we obtained the data set in March 2012 for data through December 2010 to ensure that nearly all claims in the data set had been collected and adjudicated for our entire study period.
We identified AF, comorbidities, and procedures of interest for this analysis using previously published lists of relevant and validated International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and current procedural terminology (CPT) codes (Data Supplement). 19, 20 This study was reviewed by the Duke University Health System Institutional Review Board (IRB) and determined to be exempt from IRB review.
Study Cohort
We identified the first inpatient or outpatient encounter with a primary or secondary diagnosis of AF (ICD-9-CM code 427.31) between January 1, 2006 , and December 31, 2010. To identify new AF, we excluded patients without at least 6 months of continuous health plan enrollment before this first AF encounter. Prescription claims were reviewed to identify those patients who received their first prescription for an oral formulation of a Class Ic (propafenone, flecainide) and Class III (amiodarone, sotalol, and dronedarone) AAD within 14 days after their first identified AF encounter. Therefore, patients with prior AAD were excluded. This methodology was designed to create a population of new AF and new AAD. Only prescription claims for a ≥30-day supply of the selected AAD were included. The date of the first prescription claim for the qualifying AAD was considered the index date. Patients were then excluded from the final study cohort if they were <18 years of age or had CAD (ICD-9-CM codes 410-414, 429.2, V45.81), heart failure (ICD-9-CM codes 428.xx 402.01, 402.11,402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, and 398.91), cardiomyopathy (ICD-9-CM codes 425.0, 425.1, 425.2, 425.3, 425,5, 425.7. 425.8, 425.9), ventricular arrhythmia (ICD-9-CM codes 427.1, 427.4x, 427.5), or heart transplant or left ventricular assist device (ICD-9-CM codes 37.5x, 33.6, 37.6x, V42.1) in the 6 months before the index date. Of note, patients receiving dofetilide were not included because there were only a total of 46 patients in this database who received dofetilide as their initial AAD.
Treatment Groups
Propafenone and flecainide were considered to be similar in pharmacological activity and indication, so they were combined into the one treatment group (Class Ic drugs). Therefore, four treatment groups were created based on the index AAD prescription: (1) Class Ic drugs (propafenone and flecainide), (2) amiodarone, (3) sotalol, and (4) dronedarone.
Outcomes
The primary outcome measure was time to AF hospitalization after the index date. An AF hospitalization was defined as any hospitalization in which AF was listed as the primary diagnosis. Secondary outcome measures included time to cardiovascular hospitalization and time to any hospitalization after the index date. Cardiovascular hospitalization was defined as a hospitalization with a primary diagnosis of CAD, heart failure, cardiomyopathy, cardiac arrhythmias (ICD-9-CM codes 427.xx, 426.89), or cerebral hemorrhage or stroke (ICD-9-CM codes 431-435).
Statistical Analysis
For all analyses, time 0 was considered the date of index AAD prescription. The date of the first prescription claim for the qualifying AAD was considered the index date. We determined the observed
WHAT IS KNOWN
• There is a greater risk of hospitalization in patients with atrial fibrillation (AF) versus those without, and there has been an increase in hospitalization rates among AF patients over the past several decades. • Cardiovascular hospitalizations for AF patients have been shown to be associated with a significantly greater risk of mortality.
WHAT THIS STUDY ADDS
• Because little is known about hospitalization rates associated with the use of different antiarrhythmic drugs (AADs) in clinical practice, especially among seemingly healthier AF patients (like those who are younger and do not have concomitant structural heart disease), we determined AF, cardiovascular, all-cause, and non-AF/atrial flutter cardiovascular hospitalization rates and compared them in patients receiving Class Ic drugs, amiodarone, sotalol, and dronedarone. • Risk of AF hospitalization was greater with dronedarone than Class Ic (hazard ratio [HR] 1.59; 95% confidence interval 1.13-2.24), amiodarone (HR 2.63; 1.77-3.89), and sotalol (HR 1.72; 1.17-2.54), but lower with amiodarone versus Class Ic (HR 0.68; 0.57-0.80) and sotalol (HR 0.63; 0.53-0.75). • The risk of non-AF/atrial flutter cardiovascular hospitalization was statistically significantly greater with amiodarone than Class Ic drugs (HR 1.26; 95% confidence interval 1.01-1.57), and there were no statistically significant differences between any of the other AAD treatment groups event rates for the primary and secondary outcome measures and generated Kaplan-Meier curves for each treatment group. We also determined the median time of follow-up overall and within each treatment group. For the primary analysis, Cox proportional hazards models were created to compare unadjusted and adjusted time to AF hospitalization for 4 AAD treatment groups using the intention-to-treat approach. For these analyses, 2 distinct models were created. The first compared the 3 treatments (Class Ic, amiodarone, and sotalol) on the overall cohort (identified between July 1, 2006, and December 31, 2010). Because dronedarone was not available in the United States until July 2009, a second model was fit, only among patients identified between July 1, 2009, and December 31, 2010, and used to make comparisons involving dronedarone. The selection of amiodarone, sotalol, and Class 1c drugs could be altered by the availability of dronedarone. An interaction between treatment group and time period (before or after July 1, 2009) was entered into both the unadjusted and adjusted models for the overall cohort. We censored patients whose health plan enrollment ended or who reached the end of the study period (December 31, 2010) during follow-up.
Adjusted model inverse probability-weighted estimators were used to account for potential differences in treatment allocation. Propensity scores were calculated using a multinomial logistic model (amiodarone versus Class Ic; sotalol versus Class Ic; sotalol versus amiodarone; dronedarone versus Class Ic; dronedarone versus amiodarone; and dronedarone versus sotalol) and then applied as inverse probability of treatment weights in a Cox proportional hazards model. Variables for the multinomial logistic model included the following: age; sex; inpatient versus outpatient index AF encounter; geographic region; AF as primary diagnosis versus secondary diagnosis; hospitalization in the 6 months before index prescription; year of index prescription; electric cardioversion during index AF encounter; ablation during index AF encounter; number of days from index AF encounter to index prescription, rate-controlling drug use (β-blocker, calcium channel blocker, or digoxin), QT-prolonging medication use, or anticoagulant use concomitant with or within 6 months before the index prescription; and, during the 6 months before the index prescription, a history of atrial flutter, other atrial arrhythmias, bradyarrhythmias, diabetes mellitus, hypertension, chronic or acute rheumatic heart disease, pacemaker, renal impairment, liver disease, thyroid disease, pulmonary disease, cancer, stroke, cerebral hemorrhage, depression, obesity, nonrheumatic valvular disease, bleeding, and cardiothoracic surgery. All ICD-9-CM and CPT codes used in this analysis are presented in the Data Supplement. 19, 20 Sensitivity analyses to truncate extreme propensities at the 1st and 99th percentile and at the 5th and 95th percentile were done to assess the effect of extreme propensities on results. For all tests, a P value of 0.05 was considered statistically significant. Hazard ratios (HRs) and 95% confidence intervals (CIs) are presented for all time-to-event analyses.
Secondary outcome measures were compared between treatment groups using the same approach as described for the primary outcome, including all sensitivity analyses. An additional analysis was done to assess the effect of AF or atrial flutter hospitalizations on the cardiovascular hospitalization end point by removing AF or atrial flutter hospitalizations from the definition of a cardiovascular hospitalization and rerunning the unadjusted and adjusted Cox models. In addition, for an exploratory analysis, we determined rates for electric cardioversion (ICD-9-CM procedure codes 99.61, 99.62, and 99.60; CPT codes 00410, 92960, and 92961) and cardiac ablation procedures (CPT code 93651; ICD-9-CM procedure codes 37.33, 37.34) by treatment group and generated Kaplan-Meier curves for each treatment group.
Results
Of 387 615 patients with an AF encounter between January 1, 2006, and December 31, 2010, 179 110 (46%) had <6 months of prior enrollment data or had prior AAD use, and 194 423 (50%) did not have a qualifying Class Ic or Class III AAD prescription. A total of 8562 patients were included in the final study cohort ( Figure 1 ). Baseline patient characteristics are presented in Table 1 . The median age of the overall cohort was 56 (interquartile range [IQR] 49, 61), 34% were female, and 69% were hospitalized for their index AF encounter. The median number of days from filling the index AAD prescription to the end of database enrollment was 409 days (IQR 178-758). The median follow-up period was similar for Class Ic drugs (median 450 days, IQR 203-801), amiodarone (median 418 days, IQR 173-770), and sotalol (median 479 days, IQR 242-820). As described earlier, dronedarone was first marketed in the United States in July 2009; therefore, dronedarone was only available for the last 18 months of the 5-year study period (median follow-up 157 days, IQR 70-277).
The unadjusted cumulative event rates for AF, cardiovascular, and all-cause hospitalizations by treatment group are shown in Figure 2 . Unadjusted and adjusted HRs for AF, cardiovascular, and all-cause hospitalizations are shown in Table 2 . No statistically significant interaction was found between treatment group (amiodarone, sotalol, and Class Ic) and time period (before or after dronedarone became available) in the unadjusted or adjusted models. Truncating extreme propensities at the 1st and 99th percentile and at the 5th and 95th percentile also did not change the results.
In the adjusted models, the risk of AF, cardiovascular, and all-cause hospitalizations was statistically significantly greater for patients taking dronedarone than any of the other AADs. There was no statistically significant difference in risk of AF, cardiovascular, or all-cause hospitalization between Class Ic drugs and sotalol. Amiodarone was found to be associated with a statistically significantly lower risk of AF and cardiovascular hospitalizations than Class Ic drugs and sotalol, but there was no statistically significant difference between these drugs in risk of allcause hospitalization.
The results comparing cardiovascular hospitalizations among the different AAD treatment groups changed when hospitalizations with a primary diagnosis of AF or atrial flutter were excluded (Table 2 ). In this additional analysis, the risk of non-AF/atrial flutter cardiovascular hospitalization was statistically significantly greater with amiodarone than Class Ic drugs (HR 1.26; 95% CI 1.01-1.57), and there were no longer any statistically significant differences between any of the other AAD treatment groups, including none with dronedarone.
The Kaplan-Meier rates for electric cardioversion and cardiac ablation are shown in Figure 3 . Overall, the probability of electric cardioversions at 12 months was 2.8%. There was no statistically significant difference in rates between treatment groups: 2.7% for Class Ic drugs, 2.6% for amiodarone, 3.5% for sotalol, and 1.7% for dronedarone (P=0.25). Overall, the probability of cardiac ablation procedures at 12 months was 4.0%. There was a statistically significant difference in cardiac ablation procedures by treatment group: 5.1% for Class Ic, 2.3% for amiodarone, 4.0% for sotalol, and 7.9% for dronedarone (P<0.001).
Discussion
In 2013, there were ≈479,000 hospital discharges with a primary diagnosis of AF in the United States 21 Regardless of the specific reasons for the hospitalizations, each one results in a potential burden to the patient, not to mention substantial costs to the patient, payer, and healthcare system. [5] [6] [7] [8] 22 Little is known about hospitalization rates associated with the use of different AADs in clinical practice, especially among seemingly healthier AF patients, like those who are younger and do not have concomitant structural heart disease. In this study, we compared the risk of AF, cardiovascular, and all-cause hospitalizations among patients who received Class Ic AADs (flecainide and propafenone), amiodarone, sotalol, and dronedarone for treatment of their first-identified AF event. All patients were <65 years of age and had no concomitant CAD or heart failure at baseline. The adjusted risk of AF and cardiovascular hospitalization was greatest in those receiving dronedarone and lowest in those receiving amiodarone. However, AF/atrial flutter hospitalizations were the primary driver behind the observed results in cardiovascular hospitalizations. Non-AF/atrial flutter cardiovascular hospitalization was not significantly different among AAD treatment groups, except there was a greater risk of non-AF/atrial flutter cardiovascular hospitalization with amiodarone versus Class Ic drugs. There were no differences in all-cause hospitalizations among Class Ic drugs, amiodarone, and sotalol, but there was an increased risk associated with dronedarone compared with all other AADs. There are many potential reasons for these differences in hospitalization rates, including differences in side effects and efficacy of each drug in this patient population. Therefore, our results should be cautiously interpreted. Additional studies are needed to confirm our findings and focus on potential explanations for differences in hospitalization rates for different AADs. Dronedarone was approved in the United States for the reduction of cardiovascular hospitalizations in patients with paroxysmal or persistent AF who had associated cardiovascular risk factors, such as being >70 years of age, reduced ejection fraction, hypertension, diabetes mellitus, or prior stroke. This labeled indication was based primarily on the results of the Effect of Dronedarone on Cardiovascular Outcomes in High-Risk Patients With Atrial Fibrillation or Atrial Flutter trial, which found that dronedarone use compared with placebo was associated with a significantly lower risk of cardiovascular hospitalization (HR 0.74; 95% CI 0.67-0.82) that was primarily driven by a reduction in AF hospitalizations. 23 Post-hoc analyses found a significant reduction in AF hospitalization (HR 0.63; 95% CI 0.55-0.72) and non-AF/atrial flutter hospitalizations (HR 0.86; 95% CI 0.75-0.97) with dronedarone versus placebo, but no difference in noncardiovascular hospitalizations (HR 0.98; 95% CI 0.87-1.11). 11 No analysis of non-AF/atrial flutter cardiovascular hospitalizations was performed. Few studies have assessed the use or associated outcomes of dronedarone in clinical practice, and to our knowledge, only one study assessed the effect of dronedarone on hospitalizations. 13, 24, 25 Kim et al compared the mean number of AF, cardiovascular, and all-cause hospitalizations in AF patients before and after the initiation of dronedarone. There was a statistically significantly lower mean number of AF, cardiovascular, and all-cause hospitalizations in the 1 year after dronedarone initiation compared with the 1 year before dronedarone was approved for market. 13 The mean age of the population was 68 years, 36% of patients had CAD, and 12% had heart failure; therefore, Kim et al's study population was different from our study population. 13 Patients in our study who received dronedarone were all <65 years of age, none had heart failure, 5% had prior stroke, and 19% had diabetes mellitus. Approximately 60% of our patients had a history of hypertension, but we were unable to determine AF type (paroxysmal, persistent, or permanent) from claims data; as a result, some of the patients in our study who received dronedarone may not have fit with the labeled indication for dronedarone. These patients were the first in the United States to receive dronedarone in clinical practice, and it is common for newly marketed drugs to be used off-label. Additionally, because dronedarone was newly marketed, less was known about potential side effects and risks in a real-world setting. Therefore, it is possible that some of the patients in our study who received dronedarone were not optimal candidates, and this may account for why some had an increased risk of hospitalization. We also found a higher rate of cardiac ablation procedures in patients who received dronedarone versus any of the other AADs. Although some of these ablations may not have been AF ablations, this may indicate greater failures with dronedarone either through lack of efficacy in controlling AF or intolerable side effects with dronedarone, but could also indicate that dronedarone was preferred over the other drugs before a planned ablation procedure, resulting in preferential selection that we were unable to adjust for in our analysis. Additional research is needed to determine whether the observed higher risk of hospitalizations with dronedarone as compared with other AADs persisted after 2010 when drug selection patterns may have changed as new information about dronedarone was published or as early adopters of dronedarone refined their use of the drug.
In this study, we also found no significant differences in AF, cardiovascular, or all-cause hospitalizations between Class Ic drugs (propafenone and flecainide) and sotalol, but there was a reduction in AF hospitalizations with amiodarone as compared with all other AADs. Amiodarone is often considered the most effective AAD for reducing recurrences of AF, although its efficacy in this patient population is largely unknown. Unfortunately, amiodarone is also known to have a large number of side effects, some of which may be severe enough to require discontinuation or hospitalizations for treatment. We found no differences in all-cause hospitalizations between amiodarone and Class Ic drugs or sotalol, but there was a decreased risk of cardiovascular hospitalization with amiodarone as compared with Class Ic drugs or sotalol. Nonetheless, as stated earlier, the majority of cardiovascular hospitalizations were AF-related. After removing AF/atrial flutter hospitalizations from the definition of a cardiovascular hospitalization, we actually found an increased risk of non-AF/atrial flutter cardiovascular hospitalizations with amiodarone versus Class Ic drugs, but no difference with sotalol. These results merit further evaluation, as there was a low rate of non-AF/atrial flutter cardiovascular hospitalizations in this population of younger AF patients without previously treated CAD or heart failure.
There are several limitations to this study, and as with all analyses of claims data, the results may not be generalizable beyond the population included in the database. First, there are limitations to the health information available from healthcare claims data. The use of previously vetted ICD-9-CM and CPT codes for diagnoses and procedures, coupled with stringent exclusion criteria, minimize the chances for including patients within the study population that should not be included; however, clinical data are not available, which limits our ability to identify a more specific study population and all potential confounders. The required 6-month prior enrollment period may have resulted in the erroneous exclusion of some patients with their first AF encounter and inclusion of others with more distant prior AF encounters or contraindicated comorbidities. There are also many potential reasons for a hospitalization-some for AF treatment and others for the management of AF complications. The specific reason for the hospitalization cannot be obtained or inferred from claims data. Second, we used an intention-to-treat approach for the time to hospitalization analyses, and it is possible that patients discontinued AAD therapy or switched drugs before a hospitalization event. In a prior study using a similar patient population, we found the AAD change rate during the 1 year after AAD initiation was 14% for Class Ic drugs, 8% amiodarone, 17% sotalol, and 18% dronedarone, and the AAD discontinuation rate was 40% for Class Ic drugs, 52% amiodarone, 40% sotalol, and 69% dronedarone. 26 However, it should be noted that pharmacy claims data might not capture all prescription drug fills, especially when patients make cash payments for the prescription. Third, there are many factors that affect AAD selection. We used propensity scores to adjust for drug selection bias; however, there is the possibility of unknown confounders. There is also the possibility that the introduction of dronedarone to the market in the latter part of our study period resulted in changes in AAD drug selection, but the interaction between drug treatment and time period (before versus after dronedarone introduction) was not statistically significant in any of the models, indicating that AAD selection did not change with the introduction of dronedarone. In addition, although flecainide and propafenone are similar, there is the possibility of differences in drug selection and associated outcomes that were not taken into consideration in this study. Finally, mortality is not available from the database used in this study. On death, health plan enrollment would end, but the date of enrollment end did not necessarily correlate with the date of death, nor could we confirm that enrollment ended because of death versus other reasons (such as cancellation in health insurance coverage).
In conclusion, among younger AF patients without concomitant CAD or heart failure within clinical practice, we found greater risk of AF, cardiovascular, and all-cause hospitalizations associated with dronedarone versus amiodarone, sotalol, and Class Ic drugs. Our findings indicate that dronedarone use and associated outcomes in clinical practice may differ substantially from the precedent clinical trials. Amiodarone was associated with a lower risk of AF and cardiovascular hospitalizations, but not all-cause hospitalizations. Additional research is needed to better understand the association between AADs and risk of hospitalization. 
